Nasdaq:CELU

Celularity CEO Comments on Centers for Medicare & Medicaid Services Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert…

4 hours ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

August 22, 2025 17:30 ET  | Source: Celularity, Inc. FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc.…

4 months ago